In an interview with SmartTRAK, Mesh Suture, Inc. (MSI) Founder Gregory Dumanian MD, discusses the Company and its novel suturable mesh that has the potential to change how hernias and other conditions are treated.

MSI is commercializing a novel suturable mesh that combines a mesh’s ability to distribute forces and support tissue with the precise placement and minimal foreign body presence of a suture. In a time when patients and physicians are rethinking how mesh is used in hernia treatment, MSI’s Duramesh offers the potential of retaining the durability of mesh repair with less foreign body presence. Today, the Company is running clinical trials and building evidence to support regulatory clearance in the United States. To find out more about the Company and its operation, SmartTRAK talked with Gregory Dumanian, MD, Chief of Plastic Surgery at Northwestern University’s Feinberg School of Medicine, Founder & Medical Officer of MSI and the inventor of the new technology.

Click on the following video to listen to SmartTRAK Senior Analyst Doug Devens’ interview with Dr. Dumanian, which was recorded via Zoom audio (24: 35 min). A link to download a complete transcript of the interview is also provided below.

The US market for Hemostats and Sealants regained its pre-pandemic stride in Q321 as many procedures mostly returned to normal volumes.

Procedures using surgical matrices maintained their new normal, with broad strength in both hernia and breast matrices.

Procedures using surgical matrices maintained their new normal, though the resurgence of Delta variant across the northern tier of states may put a dent in the market following deferrals of procedures in various regions as the COVID-19 Delta variant caused more procedural headwinds.

Among the many topics covered in detail in our comprehensive Q321 US Surgical Matrices Market Recap* are:

Procedures using surgical matrices rebounded to normal levels again, with broad strength in both hernia and breast matrices.

Procedures using surgical matrices returned to approximately normal levels, though the Delta variant may make that recovery short-lived, as recently observed in Texas. The US Surgical Matrices market rebounded strongly in Q221 according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* continued to lead the US Surgical Matrices market, with Becton Dickinson* (BD) bouncing back nearly as strongly.

Among the many topics covered in detail in our comprehensive Q221 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants came roaring back from its pandemic depths in Q221 as procedures returned to normal.  

As surgical procedures returned to approximately normal levels, the US Hemostats and Sealants market grew +51.1% YoY in Q221 according to SmartTRAK Financial Dashboard. Growth was strong across all segments and companies. However, the Delta variant may make that recovery short-lived, as recently observed in Texas.

Among the many topics covered in detail in our comprehensive Q221 US Hemostats and Sealants Market Recap* are:

Procedures using surgical matrices continued their recovery, with breast matrices benefiting more from comparison to the early stages of the pandemic that began last year.

Procedures using surgical matrices resumed their return to pre-COVID levels. The US Surgical Matrices market returned to growth according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie continued to lead the Surgical Matrices market while Becton Dickinson (BD), although still leading the US Hernia Matrices market, continued to slide as the hernia market lagged the recovery in breast matrices.

Among the many topics covered in detail in our comprehensive Q121 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants resumed its growth in Q121 as procedures climbed back towards normal.

While surgical procedures have not fully regained their pre-COVID levels, the US Hemostats and Sealants market grew in Q121 according to SmartTRAK Financial Dashboard. However, it continued to be a tale of two recoveries. CryoLife* and especially JNJ/Ethicon* posted solid gains for the quarter. However, as elective procedures continue to be behind pre-COVID levels, other manufacturers lagged by comparison.

The recovery in breast and hernia procedure stalled in Q420, with revenue dropping -9.2% YoY, according to BioMedGPS’ SmartTRAK Financial Dashboard. AbbVie* maintained its lead despite the effects of the pandemic, off -8.4% YoY, as its breast matrices continued to lag in the overall recovery. Becton Dickinson* (BD) slid –1.2% YoY as hernia procedures bounced back to normal levels a little faster ...

Among the many topics covered in the comprehensive Q420/FY20 US Surgical Matrices Market Recap* are:

The US market for Hemostats and Sealants continued back toward its pre-pandemic levels, gaining +20.0% QoQ and up +1.1% YoY. For FY20, the market declined, as COVID-19 delayed procedures in Q220 proved too much to overcome.

As the US Healthcare system learned to navigate the new normal and elective procedures continued their return toward COVID-19 levels, the US Hemostats and Sealants market finally exceeded pre-pandemic levels, up +1.1% YoY according to SmartTRAK Financial Dashboard. However, for the year the market was down as Q220’s delayed procedures proved too much to overcome.

Among the many topics covered in the comprehensive Q420/FY20 US Hemostats and Sealants Market Recap* are:

The US market for Hemostats and Sealants began the journey back to normalcy, slipping -0.2% YoY in Q320, as elective surgeries began to be performed again. Hemostats led the charge with Sealants not far behind.

As the US healthcare system begins to manage COVID-19 and elective procedures return toward pre-COVID-19 levels, the US Hemostats and Sealants market rebounded with a drop of only -0.2% YoY in Q320 according to SmartTRAK Financial Dashboard. Most manufacturers still experienced declines in Q320, but far narrower than the losses of Q220. Ethicon* managed a +4.5% gain in Q320 while the other manufacturers essentially treaded water with respect to Q319.

Among the many topics covered in the comprehensive Q320 US Hemostats and Sealants Market Recap* are: